667 related articles for article (PubMed ID: 23036368)
1. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
5. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
6. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
7. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
12. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
14. [Progress of research on breast cancer stem cell markers].
Liu X; Li W; Fu L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):282-4. PubMed ID: 24915825
[No Abstract] [Full Text] [Related]
15. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
17. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
19. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE
PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
